IMUX
NASDAQ HealthcareImmunic, Inc. - Common Stock
Biotechnology
Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company also develops IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.
�� 市场数据
| 价格 | $9.65 |
|---|---|
| 成交量 | 173,943 |
| 市值 | 131.45M |
| 贝塔系数 | 1.370 |
| RSI（14日） | 31.4 |
| 200日均线 | $8.63 |
| 50日均线 | $11.03 |
| 52周最高 | $15.10 |
| 52周最低 | $5.06 |
| Forward P/E | -3.06 |
| Price / Book | -17.42 |
🎯 投资策略评分
IMUX 在各投资策略中的评分。分数越高，越符合该策略目标。
🔍 策略解读
最佳匹配： 🚀 Moon Shot (89/100) — 此策略 高增长潜力（高贝塔 + 超卖）.
评分最低的策略： 🐋 Institutional Whale (2/100). 单一评分不构成买入或卖出信号 — 请结合多种视角综合判断。 了解如何解读这些评分 →
📚 了解更多
在文本中查找 IMUX in your text
粘贴任何文章、记录或帖子 — 工具将提取 IMUX 以及每一个其他隐藏的股票代码。
免责声明：本数据仅供教育和娱乐用途，不构成金融建议。市场数据可能存在延迟。在做出投资决策之前，请始终进行自己的研究。
数据最后更新： 2026-05-01.